Characteristics and outcomes of Latinx patients with COVID-19 in comparison to other ethnic and racial groups

Disparities in COVID-19 Hospitalization and ICU Admission

Saef Izzy, MD,1,2,3 Zabreen Tahir, MD,1 David J. Cote, PhD,3 Ali Al Jarrah, MD,1 Matthew Blake Roberts, MBBS,4,3 Sarah Turbett, MD,4,5 Aran Kadar, MD,6 Stelios M. Smirnakis, MD PhD,1,3 Steven K. Feske, MD,1,3 Ross Zafonte, DO,3,7,8 Jay A. Fishman, MD,3,4 Joseph El Khoury, MD2,3,4

1 Department of Neurology, Neurocritical Care, Brigham and Women’s Hospital Boston, MA
2 Center for Immunology & Inflammatory Diseases, Massachusetts General Hospital, Boston, MA
3 Harvard Medical School, Boston, MA
4 Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA
5 Department of Pathology, Massachusetts General Hospital, Boston, MA
6 Department of Medicine, Division of Pulmonary and Critical care, Newton Wellesley Hospital, Harvard Medical School
7 Department of Physical Medicine and Rehabilitation Massachusetts General Hospital, Boston, MA
8 Spaulding Rehabilitation Hospital, Charlestown, MA.

Corresponding author:
Joseph El Khoury, MD
Division of Infectious Diseases
Department of Medicine
Massachusetts General Hospital
149 13th Street
Charlestown, MA 02119
jelkhoury@mgh.harvard.edu
(617) 724-7068

Acknowledgments: The authors thank the staff of Mass General Brigham Hospitals who cared for the patients included in this study.

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Abstract

**Background:** There is limited understating of the impact of COVID-19 on the Latinx population. We hypothesized that Latinx patients would be more likely to be hospitalized and admitted to the ICU than White patients.

**Methods:** We analyzed all patients with COVID-19 in 12 Massachusetts hospitals between February 1 and April 14, 2020. We examined the association between race, ethnicity, age, reported comorbidities, and hospitalization and intensive care unit (ICU) admission using multivariable regression.

**Results:** Of 5190 COVID-19 patients, 29% were hospitalized; 33% required ICU and 4.3% died. 46% of patients were White, 25% Latinx, 14% African American, and 3% Asian American. Ethnicity and race were significantly associated with hospitalization. More Latinx and African American patients in the younger age groups were hospitalized than whites. Latinx and African Americans disproportionally required ICU, with 39% of hospitalized Latinx patients requiring ICU compared to 33% of African Americans, 24% of Asian Americans, and 30% of Whites (p<0.007). Within each ethnic and racial group, age and male gender were independently predictive of hospitalization. Previously reported pre-existing comorbidities contributed to the need for hospitalization in all racial and ethnic groups (p<0.05). However, the observed disparities were less likely related to reported comorbidities, with Latinx and African American patients being admitted at twice the rate of Whites, regardless of such comorbidities.

**Conclusions:** Latinx and African American patients with COVID-19 have higher rates of hospitalization and ICU admission than White patients. The etiologies of such disparities are likely multifactorial and cannot be explained only by reported comorbidities.

**Key words:** SARS-CoV-2, COVID-19, Disparities, Hospitalizations, Race, Ethnicity
Introduction

The health, societal, and economic impacts of coronavirus disease 2019 (COVID-19) have been felt worldwide, with nearly 12 million confirmed infections leading to more than 500,000 deaths by early July 2020, with numbers continuing to grow. Studies from China, Italy, Spain and the United States have identified several factors associated with symptomatic infection and hospitalization, with or without admission to intensive care units (ICU). Older age has been shown to significantly increase the risk for hospitalization and death. Hypertension, heart disease, obesity, and diabetes are common comorbidities associated with hospitalization in COVID-19 patients. Most of these published reports either describe the disease in relatively homogenous ethnic and racial populations, or they do not compare COVID-19 infected patients who did and did not require hospitalization.

In the United States, where a racially and ethnically diverse population has been exposed to infection in the setting of known racial and ethnic health disparities, several news reports have suggested that ethnic and racial minorities, especially Latinx and non-Latin African American individuals, may bear a higher burden of disease during the COVID-19 pandemic. These reports also propose that such disparities are due to higher rates of pre-existing comorbidities in Latinx and non-Latin African American patients. Other than these limited reports, the association between ethnicity and race, and reported pre-existing comorbidities as risk factors for hospitalization and ICU admission in COVID-19 patients, has yet to be examined in a large, ethnically and racially diverse population. In this paper, we hypothesized that there are ethnicity and race-related disparities in hospitalization and ICU admission for COVID-19 patients regardless of age and reported pre-existing comorbidities. We used medical records available from the largest not-for-profit healthcare system in Massachusetts to examine the association between age, race and ethnicity, reported pre-existing comorbidities, and the need for hospitalization and ICU admission in a large study population of COVID-19 positive patients.

Methods

Data Source

Mass General Brigham is a not-for-profit healthcare system affiliated with Harvard Medical School that comprises 12 hospitals across eastern Massachusetts. These hospitals include Massachusetts General Hospital (Boston), Brigham and Women’s Hospital (Boston), Brigham and Women’s Faulkner Hospital (Boston), Massachusetts Eye and Ear Infirmary (Boston), Spaulding Rehabilitation Network (Boston, Cambridge), McLean Hospital (Belmont), Cooley Dickinson Hospital (Northampton), Martha’s Vineyard Hospital (Oak Bluffs), Nantucket Cottage Hospital (Nantucket), Newton-Wellesley Hospital (Newton), North Shore Medical Center (Salem, Lynn, Danvers), and Wentworth-Douglass Hospital (Dover). The system cares for about a third of patients in Massachusetts.
Patient Consent Statement

The design of the study was approved by the Mass General Brigham Institutional Review Board (IRB) who deemed that the study does not include factors necessitating patient consent.

Data Collection

We used data reporting functions available through the electronic health record (Epic Systems, Verona, WI) shared by all Mass General Brigham healthcare system institutions. We collected data on all patients 18 years or older who tested positive for COVID-19 during an inpatient, outpatient, or emergency room visit between February 1, 2020 and April 14, 2020. We revisited the records on April 25, 2020 to collect follow-up data on mortality and other outcomes.

Patients who presented to Mass General Brigham institutions with symptoms of fever, cough, sore throat, fatigue, muscle aches, new anosmia, who were exposed to someone who tested positive for COVID-19, or if referred by a healthcare provider were tested per specified testing criteria/guidelines set forth by the institution. Patients were diagnosed as infected with COVID-19 if SARS-CoV-2 RNA was detected in upper or lower respiratory specimens by nucleic acid testing (NAT) assays designated for emergency use authorization (EUA) by the Food and Drug administration (FDA) and in accordance with the Centers for Disease Control and Prevention (CDC) guidelines. Each assay targets at least one SARS-CoV-2 gene region; positive results are reported for each assay as defined by the manufacturer or reference laboratory.

Endpoints

Hospitalization at any time during the course of the illness and admission to an ICU at any time during hospitalization were primary endpoints. Patients who were discharged home initially but were admitted later were categorized as hospitalized patients. Patients hospitalized for longer than the follow-up period were censored for study outcomes.

Covariates

We extracted the following covariates from the electronic health records for all patients: age, gender, patient-reported race (White, African American, Asian American or Pacific Islander, Other, or Unknown), patient-reported ethnicity (Latin or non-Latin), smoking status, and the presence of recorded metabolic diseases including obesity (as measured by body mass index [BMI]), diabetes mellitus, and hyperlipidemia. The presence of organ-specific disease included hypertension, coronary heart disease, congestive heart failure, chronic obstructive pulmonary disease, asthma,
interstitial lung disease, cerebrovascular disease, chronic kidney disease, end stage renal disease, malignancy including hematologic malignancy (lymphoma, leukemia), HIV, and history of organ or bone marrow transplantation. Missing data were imputed by multiple imputation using the Amelia package in R. The multiple-imputation models used all baseline data. BMI and smoking status for all patients were also imputed by multiple-imputation models using R, and 10 imputations were carried out in total under the assumption that data were missing at random. Data for median household income and population density were obtained from census data reported by the census bureau for the state of MA, and were linked to patient by zip code of reported residential address. Because immunocompromised patients generally demonstrate increased susceptibility to respiratory viral infections, we analysed our study population of patients for history of solid organ transplantation (SOT), lymphoma, leukemia or HIV to assess whether these factors were associated with hospitalization or ICU admission.

**Statistical Analysis**

As appropriate, descriptive analyses of variables are presented as proportions or medians with interquartile range (IQR) for all endpoints (not hospitalized, hospitalized, admitted to ICU). Categorical data were compared using Chi-squared tests, while t-test was used for continuous variables to identify univariable associations. Multivariable logistic regression models were constructed to identify factors associated with hospitalization and ICU admission. We tested our assumption that data were missing at random by constructing logistic regression models for missingness using all of the variables included in multiple imputations. We further examined the association between racial and ethnic background and hospital admission by comparing proportions of endpoints for each 5-year age interval from 18 to 90. We also examined the association between racial and ethnic background, pre-existing comorbidities, and hospitalization or ICU admission by stratifying by number of baseline comorbidities (0 vs. ≥1) and race and ethnicity. We further performed a sensitivity analysis with adjustment for socioeconomic status as a predictor for hospitalization/ICU admission for patients from Massachusetts state with median household income data available. Patients with median household income less than 20th percentile ($53,335) were classified to have low SES as a dichotomous variable. Statistical significance was defined as p<0.05 for all analyses, and all statistical analysis was completed using R v 3.6.1. We graphed the geographic representation of the confirmed COVID patients during our study using Microsoft Excel version 16.36.
Results

Characteristics of all Hospitalized vs. Non-Hospitalized Patients irrespective of race or ethnicity

A total of 5,190 patients were diagnosed with laboratory confirmed COVID-19 in the time frame of the study and were included in our analysis (Figure 1). Out of the total study population, 1,489 (28.6%) were hospitalized. Overall, hospitalized patients were more likely to be male (56% vs. 42%, p<0.001) and older (median 62 vs. 47 years, p<0.001) compared to non-hospitalized patients. Hospitalized patients were also more likely to be obese (34% vs. 17% BMI 30-40 kg/m², p<0.001), with on average more cardiovascular and pulmonary risk factors, and more comorbid conditions compared to non-hospitalized patients (Table 1). The most common comorbidities in the hospitalized study population were hypertension (48%), hyperlipidemia (36%), diabetes (33%), and obstructive lung disease (15%). The mortality rate was higher in hospitalized compared to non-hospitalized patients (15% vs. 0.2%, p<0.001). Our test of the missing at random assumption demonstrated significant predictors of missingness for all variables for which imputation was conducted.

Distribution of Race and Ethnicity Among Hospitalized Patients

Among the total COVID-19 positive patient study population, 2,404 (46%) were White, 1,309 were Latinx (25%), 719 were African American (14%) and 177 were Asian American (3%). Ethnicity and race were significantly associated with the rate of hospitalization. Latinx and African American patients were more likely to be admitted to the hospital than White patients (35.9% and 29.1%, respectively, vs. 25.8% for White patients). Overall Latinx, African American, and Asian American hospitalized patients were younger compared to White patients (median age 52, 60 and 61, vs. 72 respectively, p<0.001, Table 2).

Age, reported pre-existing comorbidities and hospitalization by race

Subgroup analyses of the ages between 18-85 at 5-year intervals showed that in each age group, Latinx and African American patients were more likely to be admitted as a result of COVID-19 compared to White patients (p<0.05 for each comparison, Figure 2). For example, among those 18-40 and 40-60 years old, Latinx and African American patients were admitted to the hospital at the rates of (22% and 13% vs. 6%, and 46% and 38% vs. 20%, in comparison to. White patients respectively, p<0.001 for each comparison). We observed similar, among those aged >60 (Supplementary Table 1).

With regard to reported comorbidities, hospitalized Latinx patients were more likely to be obese in the range of 30-40 kg/m² (41% compared to 31% among White and 33% among African American patients, p<0.001). However, the proportions of White, Latinx and African American patients who were in range of >40 kg/m² were similar. White patients had higher rates of reported hyperlipidemia, hypertension, obstructive lung disease, coronary artery disease, congestive heart
failure, chronic kidney disease and malignancy compared with other groups (p<0.05, Table 2, Supplementary Table 2). When stratified by baseline reported comorbidities, Latinx and African American patients were admitted at twice the rate of Whites, regardless of whether they had reported preexisting comorbidities (p<0.001, Table 3).

Compared to non-hospitalized patients, univariable logistic regression stratified by race identified pre-existing comorbidities including metabolic, cardiovascular, cerebrovascular, pulmonary and kidney disease as predictors for hospitalization in all racial and ethnic groups (p<0.05, Supplementary Table 3). After adjustment for age, gender, baseline comorbidities, and racial and ethnic background in multivariable regression analysis, older age, male gender, diabetes (OR=1.87, 95%CI: 1.40-2.50 for White, OR=2.66, 95%CI: 1.70-4.14 for Latinx, OR=1.74, 95%CI: 1.01-3.01 for African American patients), chronic kidney disease (OR 2.61, 95%CI: 1.78-3.83 for White patients), interstitial lung disease (OR=9.09, 95% CI: 1.02-81.32 for white patients) and transplantation (OR=8.12, 95%CI: 1.46-45.21 for African American patients) were independently associated with hospitalization (Table 4). Most of these predictors remained significant after adjustment for socioeconomic status (Supplementary Table 4).

**Median household income and population density by patient zip code**

Based on patients’ zip-code data, 43% of all the patients who tested positive lived in zip codes with median income between $50,000-$75,000, of which 35% were hospitalized. A higher proportion of hospitalized Latinx and African American patients lived in those zip codes (65% and 50% respectively, compared to 38% of White patients, Figure 3a, Supplementary Table 7). Interestingly, smaller proportions of patients living in zip codes with income <$50,000 were hospitalized (Supplementary Table 6). In addition, residence in a zip-code with greater density of living per household was correlated with a higher likelihood of hospitalization (Figure 3b, Supplementary Table 8). In our study population, 44% of admitted patients were from areas residence with population density >10,000/square mile.

**Patients with a History of Solid Organ Transplant, Lymphoma and HIV**

A history of solid organ transplantation was associated with a significantly increased risk for hospitalization (p<0.001). Of the 22 transplant patients who were COVID-19 positive (12 kidney recipients, three liver recipients, four heart recipients, two lung recipients and one heart/lung recipient) seventeen (77%) were admitted. In contrast, HIV, lymphoma or a history of leukemia were not associated with increased risk for hospitalization or ICU admission (Supplementary Table 9). A possible difference between SOT patients and those with HIV or a history of lymphoma or leukemia, is that SOT patients were universally immunosuppressed at the time of infection while the degree of immune impairment for other groups was likely more heterogeneous.
Distribution of Race and Ethnicity Among ICU Admitted Patients

Latinx and African American patients disproportionally required admission to the ICU compared to White patients. Overall, 39% of hospitalized Latinx patients required admission to the ICU compared to 33% of African American patients, 24% of Asian American patients and 30% of White patients (p<0.007, Table 2).

The presence of reported metabolic or organ-specific comorbidities was not significantly associated with need for ICU admission (Supplementary table 5). In multivariable regression analysis, age greater than 60 years old (OR=2.71, 95%CI: 1.44-5.09 for Latinx, OR=5.49, 95%CI: 1.46-20.63 for African American patients) and obesity with BMI >40kg/m² (OR=3.43, 95%CI: 1.45-7.67 for Latinx patients), and diabetes (OR=2.78, 95%CI: 1.08-7.11 for African American patients) were identified as significant predictors of ICU admission (Table 5). In addition to these predictors, low median household income was as a significant predictor for ICU admission in White patients (OR=2.50, 95% CI: 1.39-4.52) after adjustment for socioeconomic status (Supplementary Table 6).

Discussion

In spite of aggressive efforts by the medical and public health communities worldwide, understanding of the overall impact of the COVID-19 pandemic remains limited. Based on data from China, Italy, and Spain, and preliminary data from the United States, patients who are 60 years or older are more vulnerable to COVID-19, with higher morbidity and mortality. Furthermore, patients with other comorbidities, such as cardiovascular disease and hypertension, are more likely to be hospitalized and die from the infection. This evidence mostly derives from studies performed in racially and ethnically homogeneous populations. The impact of the disease in an ethnically and racially diverse population has not been fully explored.

Anecdotal and news reports and a report from the UK suggest that racial and ethnic minorities may be more likely to contract COVID-19, and more likely to suffer poor outcomes as a result of infection. Price-Haywood et al. and others showed that the majority of patients hospitalized with COVID-19 and of those who died in a Louisiana study population were African American. Our firsthand clinical experience with COVID-19 patients indicate that in addition to African American patients, a higher percentage of COVID-19 Latinx patients required hospitalization and critical care admission. To examine this issue, we investigated the impact of COVID-19 on the patient population covered by our group of hospitals, which serve a diverse and broad population of Eastern Massachusetts similar to the racial and ethnic compositions of many large metropolitan areas of the United States. We confirmed that age, male gender and obesity are indeed important risk factors.
for worse outcomes after COVID-19 infection, and that the presence of reported comorbid medical conditions is an important contributing factor to hospitalization among all ethnic and racial groups.

Three additional important findings emerged from our study. First, analysis of our large study population confirmed our firsthand clinical experience and showed indeed that Latinx and African American patients are at higher risk of being hospitalized and admitted to ICU level of care with COVID-19, than White patients. A second important finding is that the differences observed between Latinx and African American vs. White patients occur at all age groups and are not only limited to the “higher risk” older age groups identified in prior studies. A third important finding is that the observed disparities appear to be less likely related to reported pre-existing medical comorbidities, since Latinx and African American patients who tested positive for COVID-19 were admitted at twice the rate of Whites, regardless of whether they had reported comorbidities or not. In addition, the proportion of White patients who had reported comorbidities such as hyperlipidemia, hypertension, obstructive lung disease, coronary heart disease, cerebrovascular disease was at least as great as the proportions of Latinx and African American patients who have these comorbidities.

The underlying etiology of such disparity in hospitalization from COVID 19 between Latinx and African American vs. White patients is likely multifactorial. First, patients from these historically disadvantaged racial and ethnic groups may be less likely to be insured than White patients. Immigration status could also play another role in restricting access of racial and ethnic minority patients to health insurance coverage and increase their challenges in finding a source of care to get tested or accessing COVID related treatments. Therefore, they may have presented at a later, more severe phase of the disease and therefore required hospitalization. In support of this, when we analyzed the zip-code of residence of these patients we found a close correlation between residence in a zip code of low median income and greater density of living in the same household with higher rate of hospitalization. In general, lower income patients tend to defer seeking healthcare for fear of financial burden and/or limited health care access and quality.

Second, it is possible that Latinx and African American patients with COVID 19 have a higher severity of reported comorbidities. Our data do not show that such disparities in hospitalization can be explained by the presence of reported comorbidities. However, there are limitations to our interpretation of these data. Because our findings are based on reported data in the medical records, they do not take into account the severity of the preexisting conditions, which is difficult to quantify in such a large study population. It is likely that the severity of certain underlying comorbidities is higher in ethnic and racial minorities than in White patients, perhaps due to previously described healthcare disparities, or to issues with medication use and adherence.

Third, other issues of stress and allostatic load that could impact health, which were out of the scope of our observational study may also be contributing factors to the observed disparities and require further investigation. These include crowded housing conditions as we alluded above, or the type of employment where exposure to COVID 19 could possibly be more common.

Our study has several possible limitations. First, this is a registry database study from a single mixed health system (with primary and tertiary institution) using structured data captured in the
electronic medical record. This study may also underrepresent COVID-19 patients who do not seek medical attention or have whose medical data are stored at other facilities. However, the strengths of this study include a large, diverse study population of COVID-19 positive patients from a wide geographic region that allowed us to analyze a large number of Latinx, African American, Asian American in addition to White patients. We were also able to collect detailed sets of variables on each patient, including factors that predict hospitalization and ICU-level care, which allows for multivariable adjustment. Follow up identified a number of outcome events, including deaths and ICU-level admissions. While we acknowledge the limitations of our study, reporting data based on societal understanding of race and ethnicity, using patient self-reported race and ethnicity, is an important step in highlighting existing disparities in COVID-19 treatment and try to mitigate contributing factors for the future. 38,39

Our findings also could have immediate policy implications, since it would be crucial to target the most vulnerable groups when testing or vaccination strategies are devised to limit further spread of COVID-19 and minimize its impact. This is especially relevant with the new surge in the numbers of COVID cases in states where Latinx patients constitute a significant portion of the population such as Florida and Texas.
References

1. McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N Engl J Med 2020.

2. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020.

3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020.

4. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020;382:1199-207.

5. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.

6. Legido-Quigley H, Mateos-Garcia JT, Campos VR, Gea-Sanchez M, Muntaner C, McKee M. The resilience of the Spanish health system against the COVID-19 pandemic. Lancet Public Health 2020.

7. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA 2020.

8. Rosenbaum L. Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's Front Line. N Engl J Med 2020.

9. Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. JAMA 2020.

10. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020.

11. Team CC-R. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:343-6.

12. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020;12:6049-57.

13. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.

14. Perez AD, Hirschman C. The Changing Racial and Ethnic Composition of the US Population: Emerging American Identities. Popul Dev Rev 2009;35:1-51.

15. Ferdinand KC, Nasser SA. African American COVID-19 Mortality: A Sentinel Event. J Am Coll Cardiol 2020.

16. Yancy CW. COVID-19 and African Americans. JAMA 2020.
17. Choi YJ, Lee HY, An S, Yoon YJ, Oh J. Predictors of Cervical Cancer Screening Awareness and Literacy Among Korean-American Women. J Racial Ethn Health Disparities 2020;7:1-9.

18. How covid-19 is a perfect storm for African American Americans. 2020. at https://www.washingtonpost.com/opinions/2020/04/26/we-must-address-social-determinants-affecting-African-American-community-defeat-covid-19/.

19. LatinXs and African Americans Are Hardest Hit by COVID-19 in New York City. U.S.News, 2020. at https://www.usnews.com/news/national-news/articles/2020-04-08/coronavirus-disproportionally-kills-LatinXs-and-African-Americans-in-new-york-city.

20. Interim guidelines for collecting, handling, and testing clinical specimens from persons for Coronavirus disease 2019 (COVID-19). April 14, 2020. Accessed April 21, at https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html.

21. Emergency Use Authorization. April 21, 2020. Accessed April 21, at https://www.fda.gov/media/136314/download.

22. Honaker J KG, African Americanwell M. Amelia II: A Program for Missing Data. Journal of Statistical Software 2011;45(7), 1–47.

23. Income statistics and demographics for States, Counties, Cities and Zip Codes. 2020. (Accessed 04/29/2020, 9PM, 2020, at https://cubit-data.myshopify.com/)

24. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria., 2019. at https://www.R-project.org/.

25. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis 2020.

26. Eboni G. Price-Haywood MD, M.P.H., Jeffrey Burton, Ph.D., Daniel Fort, Ph.D., and Leonardo Seoane, M.D. Hospitalization and Mortality among African American Patients and White Patients with Covid-19. NEJM 2020.

27. Population Health Statistics: Race and ethnicity reports. Mass.gov, 2020. at https://www.mass.gov/lists/population-health-statistics-race-and-ethnicity-reports.

28. Braveman PA, Cubbin C, Egerter S, Williams DR, Pamuk E. Socioeconomic disparities in health in the United States: what the patterns tell us. Am J Public Health 2010;100 Suppl 1:S186-96.

29. Heisler M, Faul JD, Hayward RA, Langa KM, Blaum C, Weir D. Mechanisms for racial and ethnic disparities in glycemic control in middle-aged and older Americans in the health and retirement study. Arch Intern Med 2007;167:1853-60.

30. Wong MD, Shapiro MF, Boscardin WJ, Ettner SL. Contribution of major diseases to disparities in mortality. N Engl J Med 2002;347:1585-92.

31. Xie Z, St Clair P, Goldman DP, Joyce G. Racial and ethnic disparities in medication adherence among privately insured patients in the United States. PLoS One 2019;14:e0212117.
32. Alsabbagh MH, Lemstra M, Eurich D, et al. Socioeconomic status and nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Value Health 2014;17:288-96.

33. Zhang Y, Baik SH. Race/Ethnicity, disability, and medication adherence among medicare beneficiaries with heart failure. J Gen Intern Med 2014;29:602-7.

34. Duru OK, Harawa NT, Kermah D, Norris KC. Allostatic load burden and racial disparities in mortality. J Natl Med Assoc 2012;104:89-95.

35. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med 1998;338:171-9.

36. Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19: A systematic review. Diabetes Metab Syndr 2020;14:655-9.

37. Muscogiuri G, Pugliese G, Barrea L, Savastano S, Colao A. Commentary: Obesity: The "Achilles heel" for COVID-19? Metabolism 2020;108:154251.

38. Chowkwanyun M, Reed AL, Jr. Racial Health Disparities and Covid-19 - Caution and Context. N Engl J Med 2020.

39. Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and Racial/Ethnic Disparities. JAMA 2020.
Table and Figure Legends

**Table 1.** Characteristics of all COVID-19 positive patients in the Mass General Brigham healthcare system.

**Table 2.** Baseline characteristics by race and ethnicity among admitted COVID-19 patients.

Table 3. Rate of hospitalization among all COVID-19 patients by baseline comorbidities and race and ethnicity.

**Table 4.** Multivariable logistic regression model predicting hospital admission among patients with COVID-19.

**Table 5.** Multivariable logistic regression model predicting ICU admission among hospitalized patients with COVID-19.

**Figures:**

**Figure 1.** Zip code distribution of laboratory confirmed COVID-19 patients at 12 hospitals comprising the Mass General Brigham healthcare system in Massachusetts.

**Figure 2.** Percent of COVID-19 patients hospitalized by race and ethnicity and age.
**Figure 3a-b.** Median household income and population density by patient zip code among COVID-19 patients admitted at the Mass General Brigham healthcare system in Massachusetts:

Figure shows a) household income b) population density per zip code distribution for Latinx, African American and White patients who were admitted.

*The household income and population density reported are obtained from county-level census data.

**Conflict of Interests:**

Dr. Ross Zafonte serves on the Scientific Advisory Board of Oxeia Biopharma, Biodirection, EIMINDA, and Myomo. He also evaluates patients in the MGH Brain and Body-TRUST Program which is funded by the NFL Players Association. The remaining authors declare no conflict of interests.
Table 1. Characteristics of all COVID-19 positive patients in the Mass General Brigham healthcare system.

|                     | All patients (N=5190) | Hospitalized (N=1489) | Not Hospitalized (N= 3701) | p-value |
|---------------------|-----------------------|-----------------------|----------------------------|---------|
| **Median Age (IQR, years)** | 52 (36-66)           | 62 (50-76)            | 47 (33-60)                 | <0.001  |
| **Age categories**   |                       |                       |                            |         |
| 18-40 years         | 1617 (31%)            | 201 (13.5%)           | 1416 (38%)                 | <0.001  |
| 41-60 years         | 1867 (36%)            | 487 (33%)             | 1380 (37%)                 |         |
| >60 years           | 1706 (33%)            | 801 (54%)             | 905 (25%)                  |         |
| **Male Gender**     | 2378 (46%)            | 840 (56%)             | 1538 (42%)                 | <0.001  |
| **Race**            |                       |                       |                            | <0.001  |
| White               | 2404 (46%)            | 620 (42%)             | 1784 (48%)                 |         |
| Latinx              | 1309 (25%)            | 470 (32%)             | 839 (23%)                  |         |
| African American    | 719 (14%)             | 209 (14%)             | 510 (14%)                  |         |
| Others              | 581 (11%)             | 140 (9%)              | 441 (12%)                  |         |
| Asian American      | 177 (3%)              | 50 (3.4%)             | 127 (3.4%)                 |         |
| **Comorbidities**   |                       |                       |                            |         |
| **BMI***             |                       |                       |                            | <0.001  |
| <=30                | 1844 (35.5%)          | 823 (55%)             | 1020 (27.5%)               |         |
| 30-40               | 1143 (22%)            | 511 (34%)             | 632 (17%)                  |         |
| >40                 | 232 (4.5%)            | 111 (7.5%)            | 122 (3%)                   |         |
| **Smoking status**  |                       |                       |                            | <0.001  |
| Current             | 213 (4%)              | 64 (4.3%)             | 149 (4%)                   |         |
| Former              | 1090 (21%)            | 447 (30%)             | 643 (17%)                  |         |
| Never               | 3044 (59%)            | 801 (54%)             | 2243 (61%)                 |         |
| **Diabetes mellitus** | 969 (19%)            | 497 (33%)             | 472 (13%)                  | <0.001  |
| **Hyperlipidemia**  | 1273 (25%)            | 534 (36%)             | 739 (20%)                  | <0.001  |
| **Hypertension**    | 1617 (31%)            | 712 (48%)             | 905 (24.5%)                | <0.001  |
| **Obstructive lung disease** | 624 (12%)          | 225 (15%)             | 399 (11%)                  | <0.001  |
| **Interstitial lung disease** | 13 (0.3%)          | 11 (0.7%)             | 2 (0.05%)                  | <0.001  |
| **Coronary artery disease** | 257 (5%)            | 145 (10%)             | 112 (3%)                   | <0.001  |
| CHF                 | 136 (3%)              | 86 (6%)               | 50 (1.4%)                  | <0.001  |
| **Cerebrovascular disease** | 141 (3%)            | 73 (5%)               | 68 (2%)                    | <0.001  |
| **Obstructive sleep apnea** | 201 (4%)            | 81 (5.4%)             | 120 (3%)                   | 0.0003  |
| CKD                 | 281 (5%)              | 184 (12%)             | 97 (2.6%)                  | <0.001  |
| **Transplantation** | 22 (0.4%)             | 17 (1%)               | 5 (0.1%)                   | <0.001  |
| **Auto-immune diseases** | 158 (3%)            | 61 (4%)               | 97 (2.6%)                  | 0.007   |
| Malignancy          | 342 (7%)              | 115 (8%)              | 227 (6%)                   | 0.04    |
| **Total comorbidities** |                       |                       |                            | <0.001  |
| 0                   | 2402 (46%)            | 434 (29%)             | 1968 (72%)                 |         |
| 1-2                 | 1668 (32%)            | 519 (35%)             | 1149 (31%)                 |         |
| >2                  | 1120 (22%)            | 536 (36%)             | 584 (16%)                  |         |
| Death               | 225 (4.3%)            | 218 (15%)             | 7 (0.2%)                   | <0.001  |

IQR=Interquartile range, COPD=chronic obstructive pulmonary disease, CHF=congestive heart failure, CKD=chronic kidney disease, ESRD=End stage renal disease

*missing for 38% of population

**missing for 16% of population
| Characteristics                  | White (N=620) | Latinx (N=470) | African American (N=209) | Asian American (N=50) | Others (N=140) | p-value |
|----------------------------------|---------------|----------------|--------------------------|-----------------------|----------------|---------|
| Median age (IQR) - years         | 72 (60-83)    | 52 (41-65)     | 60 (50-70)               | 61 (46-73)            | 60 (47-75)     | <0.0001 |
| Age category                     |               |                |                          |                       |                | <0.0001 |
| 18-40 years                      | 39 (6%)       | 106 (22%)      | 28 (13%)                 | 7 (14%)               | 21 (15%)       |         |
| 41-60 years                      | 124 (20%)     | 214 (46%)      | 79 (38%)                 | 18 (36%)              | 52 (37%)       |         |
| >60 years                        | 457 (74%)     | 150 (32%)      | 102 (49%)                | 25 (50%)              | 67 (48%)       |         |
| Male Gender                      | 343 (55%)     | 265 (56%)      | 111 (53%)                | 31 (62%)              | 90 (64%)       | 0.25    |
| Comorbidities                    |               |                |                          |                       |                |         |
| Last BMI (kg/m^2) *              |               |                |                          |                       |                | 0.0002  |
| <=30                             | 373 (60%)     | 219 (47%)      | 115 (55%)                | 38 (76%)              | 78 (56%)       |         |
| 30-40                            | 193 (31%)     | 194 (41%)      | 70 (33%)                 | 9 (18%)               | 45 (32%)       |         |
| >40                              | 47 (8%)       | 37 (8%)        | 18 (9%)                  | 0 (0%)                | 9 (6%)         |         |
| Smoking status **                |               |                |                          |                       |                | <0.0001 |
| Current                          | 32 (5%)       | 16 (3%)        | 13 (6%)                  | 1 (2%)                | 2 (1%)         |         |
| Former                           | 273 (44%)     | 76 (16%)       | 57 (27%)                 | 10 (20%)              | 31 (22%)       |         |
| Never                            | 280 (45%)     | 308 (66%)      | 116 (56%)                | 33 (66%)              | 64 (46%)       |         |
| Comorbidities                    |               |                |                          |                       |                |         |
| Diabetes mellitus                | 208 (34%)     | 151 (32%)      | 80 (38%)                 | 18 (36%)              | 40 (28%)       | 0.38    |
| Hyperlipidemia                   | 296 (48%)     | 126 (27%)      | 59 (28%)                 | 21 (42%)              | 32 (23%)       | <0.0001 |
| Hypertension                     | 363 (59%)     | 159 (34%)      | 115 (55%)                | 26 (52%)              | 49 (35%)       | <0.0001 |
| Obstructive lung disease         | 124 (20%)     | 49 (10%)       | 32 (15%)                 | 8 (16%)               | 12 (8%)        | <0.0001 |
| Interstitial lung disease        | 7 (1%)        | 3 (0.6%)       | 1 (0.5%)                 | 0 (0%)                | 0 (0%)         | 0.56    |
| Coronary artery disease          | 98 (16%)      | 23 (5%)        | 11 (5%)                  | 6 (12%)               | 7 (5%)         | <0.0001 |
| CHF                              | 55 (9%)       | 10 (2%)        | 16 (8%)                  | 2 (4%)                | 3 (2%)         | <0.0001 |
| Cerebrovascular disease          | 42 (7%)       | 12 (3%)        | 12 (6%)                  | 1 (2%)                | 6 (4%)         | 0.02    |
| Obstructive sleep apnea          | 52 (8%)       | 11 (2%)        | 11 (5%)                  | 1 (2%)                | 6 (4%)         | 0.0003  |
| CKD                              | 114 (18%)     | 34 (7%)        | 24 (11%)                 | 5 (10%)               | 7 (5%)         | <0.0001 |
| Transplantation                  | 7 (1%)        | 8 (2%)         | 7 (3%)                   | 0 (0%)                | 0 (0%)         | 0.07    |
| Auto-immune diseases             | 36 (6%)       | 15 (3%)        | 8 (4%)                   | 0 (0%)                | 2 (1%)         | 0.04    |
| Malignancy      | 77 (12%) | 19 (4%) | 12 (6%) | 0 (0%) | 7 (5%) | <0.0001 |
|-----------------|----------|---------|---------|--------|--------|---------|
| Total comorbidities | 109 (18%) | 198 (26%) | 55 (26%) | 15 (30%) | 57 (41%) | <0.0001 |
| 0               | 224 (36%) | 151 (32%) | 73 (35%) | 16 (32%) | 55 (39%) |
| 1-2             | 287 (46%) | 121 (26%) | 81 (39%) | 19 (38%) | 28 (20%) |
| >2              | 184 (30%) | 182 (39%) | 68 (33%) | 12 (24%) | 38 (27%) | 0.007   |

| Requiring critical care | 184 (30%) | 182 (39%) | 68 (33%) | 12 (24%) | 38 (27%) | 0.007   |

| Outcome          | 140 (23%) | 33 (7%) | 27 (13%) | 3 (6%) | 15 (11%) | <0.0001 |
|------------------|-----------|---------|---------|--------|---------|---------|
| Discharged to home | 259 (42%) | 299 (64%) | 115 (55%) | 32 (64%) | 92 (66%) | <0.0001 |
| Discharged to SNF | 82 (13%) | 19 (4%) | 15 (7%) | 2 (4%) | 8 (6%)  | <0.0001 |
| Discharged to rehab/STF | 33 (5%) | 18 (4%) | 8 (4%) | 3 (6%) | 5 (3%)  | 0.69    |
| Still in hospital | 106 (17%) | 101 (21%) | 44 (21%) | 10 (20%) | 20 (14%) | 0.19    |
| Length of stay, days, median (IQR) | 8 (5-13) | 7 (4-14) | 7 (4-13) | 7.5 (5-12) | 7 (4-12) | 0.57    |

SNF=skilled nursing facility, STF= short term facility, BMI=Body mass index

*data missing for 3% of population **data missing for 12% of population
Table 3. Rate of hospitalization among all COVID-19 patients by baseline comorbidities and race and ethnicity.

| Comorbidity count per patient | White (N=2404) | Latinx (N=1309) | African American (N=719) | p-value* |
|-------------------------------|----------------|----------------|--------------------------|----------|
|                               | Hospitalized   | Hospitalized   | Hospitalized             |          |
| 0                             | 109/939 (12%)  | 198/681 (29%)  | 55/319 (17%)             | <0.0001  |
| ≥1                            | 511/1465 (35%) | 272/628 (43%)  | 154/400 (38%)            | 0.001    |

*Comparing the patients hospitalized for different races
Table 4. Multivariable logistic regression model predicting hospital admission among patients with COVID-19.

| Variables                  | White (N=2404) | Latinx (N=1309) | African American (N=719) |
|----------------------------|----------------|-----------------|--------------------------|
| Age                        |                |                 |                          |
| 18-40 years                | Reference      |                 |                          |
| 41-60 years                | 2.03 (1.37-3.01) * | 2.45 (1.83-3.28) * | 2.37 (1.41-4.00) *      |
| >60 years                  | 5.81 (3.95-8.55) * | 6.89 (4.51-10.52) * | 6.09 (3.37-11.00) *     |
| Gender                     |                |                 |                          |
| Female                     | Reference      |                 |                          |
| Male                       | 1.44 (1.17-1.78) * | 1.73 (1.33-2.24) * | 1.77 (1.20-2.60) *      |
| Smoking status             |                |                 |                          |
| Never                      | Reference      |                 |                          |
| Current                    | 1.10 (0.68-1.78) | 1.20 (0.66-2.19) | 1.23 (0.64-2.37)        |
| Former                     | 1.20 (0.95-1.51) | 0.78 (0.54-1.12) | 2.01 (1.22-3.32) *      |
| Last BMI (kg/m^2)          |                |                 |                          |
| <=30                       | Reference      |                 |                          |
| 30-40                      | 0.85 (0.66-1.08) | 1.48 (1.12-1.97) * | 1.07 (0.68-1.67)        |
| >40                        | 1.41 (0.87-2.28) | 1.51 (0.87-2.61) | 2.07 (0.90-4.73)        |
| Comorbidities              |                |                 |                          |
| Diabetes mellitus          | 1.87 (1.40-2.50) * | 2.66 (1.70-4.14) * | 1.74 (1.01-3.01) *      |
| Hyperlipidemia             | 0.93 (0.70-1.24) | 0.96 (0.61-1.52) | 0.63 (0.35-1.10)        |
| Hypertension               | 1.01 (0.75-1.37) | 1.20 (0.77-1.89) | 0.73 (0.45-1.32)        |
| Obstructive lung disease   | 1.30 (0.95-1.76) | 1.06 (0.65-1.71) | 1.01 (0.55-1.85)        |
| Interstitial lung disease  | 9.09 (1.02-81.32) * | 6.12 (0.56-66.47) | 3.3e+6 (0.000-NA)       |
| Coronary artery disease    | 1.44 (0.99-2.09) | 1.16 (0.52-2.59) | 0.51 (0.14-1.78)        |
| CHF                        | 1.13 (0.69-1.84) | 1.65 (0.49-5.61) | 2.22 (0.69-7.20)        |
| Cerebrovascular disease    | 1.22 (0.75-1.99) | 0.90 (0.34-2.37) | 1.10 (0.39-3.08)        |
| Obstructive sleep apnea    | 1.05 (0.68-1.63) | 0.45 (0.18-1.10) | 2.30 (0.78-6.84)        |
| CKD                        | 2.61 (1.78-3.83) * | 1.93 (0.92-4.05) | 1.31 (0.61-2.83)        |
| Transplantation            | 0.77 (0.21-2.82) | 4.07 (0.89-18.52) | 8.12 (1.46-45.21) *     |
| Auto-immune diseases       | 1.12 (0.70-1.80) | 1.23 (0.53-2.83) | 0.99 (0.31-3.22)        |
| Malignancy                 | 0.85 (0.60-1.21) | 1.08 (0.52-2.27) | 0.71 (0.28-1.76)        |
| Total comorbidities        |                |                 |                          |
| 0                          | Reference      |                 |                          |
| 1-2                        | 1.69 (1.19-2.40) * | 0.90 (0.59-1.36) | 1.71 (0.92-3.22)        |
| >2                         | 1.50 (0.81-2.78) | 0.45 (0.18-1.10) | 2.67 (0.87-8.23)        |

Significance denoted by *
Table 5. Multivariable logistic regression model predicting ICU admission among hospitalized patients with COVID-19.

| Variables                  | White (N=620) | Latinx (N=470) | African American (N=209) |
|----------------------------|---------------|----------------|--------------------------|
| **Age**                    |               |                |                          |
| 18-40 years                |               |                |                          |
| 41-60 years                | 0.89 (0.38-2.11) | 1.39 (0.81-2.37) | 2.75 (0.79-9.62)         |
| >60 years                  | 1.14 (0.50-2.59) | 2.71 (1.44-5.09) | 5.49 (1.46-20.63) *      |
| **Gender**                 |               |                |                          |
| Female                     |               |                |                          |
| Male                       | 1.27 (0.87-1.85) | 1.45 (0.96-2.20) | 1.96 (0.96-4.00)         |
| **Smoking status**         |               |                |                          |
| Never                      |               |                |                          |
| Current                    | 1.17 (0.55-2.50) | 1.56 (0.63-3.89) | 1.46 (0.34-6.27)         |
| Former                     | 1.38 (0.92-2.06) | 1.07 (0.59-1.93) | 1.83 (0.84-4.00)         |
| **Last BMI (kg/m^2)**      |               |                |                          |
| <=30                       |               |                |                          |
| 30-40                      | 1.26 (0.84-1.88) | 1.43 (0.93-2.21) | 1.66 (0.75-3.70)         |
| >40                        | 1.26 (0.63-2.53) | 3.34 (1.45-7.67) | 2.56 (0.65-10.18)        |
| **Comorbidities**          |               |                |                          |
| Diabetes mellitus          | 1.18 (0.76-1.85) | 0.80 (0.42-1.51) | 2.78 (1.08-7.11) *      |
| Hyperlipidemia             | 0.92 (0.58-1.45) | 1.40 (0.70-2.81) | 0.95 (0.40-24)          |
| Hypertension               | 0.78 (0.47-1.30) | 0.80 (0.41-1.56) | 0.34 (0.12-0.96) *      |
| Obstructive lung disease   | 0.94 (0.58-1.53) | 0.35 (0.15-0.81) * | 0.72 (0.25-2.05)       |
| Interstitial lung disease  | 1.14 (0.23-5.53) | 2.20 (0.16-31.08) | 1.47e+7 (1.04e-203 - NA)|
| Coronary artery disease    | 0.51 (0.29-0.89) * | 0.51 (0.18-1.45) | 0.65 (0.12-3.58)         |
| CHF                        | 1.42 (0.74-2.72) | 0.89 (0.19-4.20) | 2.01 (0.53-7.93)         |
| Cerebrovascular disease    | 0.64 (0.30-1.37) | 0.36 (0.08-1.57) | 0.52 (0.11-2.37)         |
| Obstructive sleep apnea    | 1.39 (0.73-2.66) | 0.14 (0.02-0.81) * | 0.75 (0.14-4.06)         |
| CKD                        | 1.06 (0.64-1.75) | 0.48 (0.19-1.19) | 1.43 (0.48-4.31)         |
| Transplantation            | 0.51 (0.05-4.75) | 3.30 (0.63-17.36) | 3.01 (0.54-16.97)        |
| Auto-immune diseases       | 0.82 (0.38-1.79) | 1.37 (0.41-4.63) | 1.92 (0.32-11.68)        |
| Malignancy                 | 0.75 (0.41-1.35) | 1.34 (0.47-3.82) | 0.82 (0.18-3.68)         |
| **Total comorbidities**    |               |                |                          |
| 0                          |               |                |                          |
| 1-2                        | 1.22 (0.64-2.34) | 0.90 (0.46-1.76) | 1.33 (0.43-4.08)         |
| >2                         | 1.83 (0.66-5.12) | 1.49 (0.39-5.70) | 1.12 (0.17-7.25)         |

Significance denoted by *
